Cytotoxic T-cell lymphoma presenting as secondary myelofibrosis with high levels of PDGF and TGF-beta.
Abe
Y
Y
Ohshima
K
K
Shiratsuchi
M
M
Honda
K
K
Nishimura
J
J
Nawata
H
H
Muta
K
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D009363:Neoplasm Proteins / Q000097:blood*; D010198:Pancytopenia / Q000209:etiology; D010982:Platelet-Derived Growth Factor / Q000032:analysis*; D011239:Prednisolone / Q000008:administration & dosage; D055728:Primary Myelofibrosis / Q000209:etiology*; D012074:Remission Induction; D013602:T-Lymphocytes, Cytotoxic / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000097:blood*; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone